Vallet S, Gouriou S, Nkontchou G, Hotta H, Vilerio M, Legrand-Quillien M C, Beaugrand M, Trinchet J C, Nousbaum J B, Dény P, Gaudy C, Goudeau A, Picard B, Payan C
Microbiologie, CHU Morvan, Brest, France.
J Viral Hepat. 2007 Feb;14(2):96-106. doi: 10.1111/j.1365-2893.2006.00773.x.
We investigated whether an HCV NS3 protease quasispecies heterogeneity was associated with progression from viral cirrhosis to hepatocellular carcinoma (HCC). The NS3 protease quasispecies structure of 10 HCV-1b cirrhotic patients (controls) was compared with that of 10 paired HCV-1b cirrhotic patients who displayed progression to HCC (cases). NS3 protease genetic complexity and diversity did not differ significantly between cases and controls. Amino acid substitutions were detected at 20 (11%) and 25 (14%) sites in at least two variants of the NS3 protease in cases and controls, respectively. Significant differences in the percentage of substituted clones were observed for 10 NS3 sites. Mutations Y56F, I71V, T72I, Q86P, P89S, S101G/D, R117H, S122G/T/N, V132I and V170I were more frequently observed in the NS3 protease sequences of controls than in those of cases. Residue V107 was substituted in NS3 cases but not in controls. However, these differences did not allow the definition of a specific NS3 profile related to HCC occurrence. The NS3 secondary structure B1-1 previously identified as potentially predictive of HCC was identified with a higher frequency in cases quasispecies (84.2%) than in controls (55.9%; P < 0.05). Our results suggest that there may be a relationship to fibrosis progression when diversity parameters are considered together with secondary structure profiles. Further investigations are required to determine the cellular interactions of HCV NS3 protease in the context of carcinogenesis.
我们研究了丙型肝炎病毒(HCV)NS3蛋白酶准种的异质性是否与从病毒性肝硬化进展为肝细胞癌(HCC)有关。将10例HCV-1b肝硬化患者(对照组)的NS3蛋白酶准种结构与10例配对的进展为HCC的HCV-1b肝硬化患者(病例组)的进行了比较。病例组和对照组之间NS3蛋白酶的遗传复杂性和多样性没有显著差异。在病例组和对照组中,分别在NS3蛋白酶的至少两个变体中的20个(11%)和25个(14%)位点检测到氨基酸替代。观察到10个NS3位点的替代克隆百分比存在显著差异。在对照组的NS3蛋白酶序列中比在病例组中更频繁地观察到Y56F、I71V、T72I、Q86P、P89S、S101G/D、R117H、S122G/T/N、V132I和V170I突变。在NS3病例组中检测到V107残基替代,而对照组中未检测到。然而,这些差异并不能确定与HCC发生相关的特定NS3特征。先前确定的可能预测HCC的NS3二级结构B1-1在病例组准种中的识别频率(84.2%)高于对照组(55.9%;P<0.05)。我们的结果表明,当将多样性参数与二级结构特征一起考虑时,可能与纤维化进展有关。需要进一步研究以确定HCV NS3蛋白酶在致癌过程中的细胞相互作用。